Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report issued on Thursday. They currently have a $18.50 price target on the biopharmaceutical company’s stock, up from their previous price target of $16.50. Chardan Capital’s price objective would suggest a potential upside of 13.92% from the stock’s current price.

FOLD has been the subject of a number of other research reports. Leerink Swann restated an “outperform” rating and issued a $17.00 price target (down previously from $18.00) on shares of Amicus Therapeutics in a research report on Saturday, September 16th. BidaskClub cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Cowen and Company restated a “buy” rating and issued a $16.00 price target (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. Finally, Robert W. Baird restated an “outperform” rating and issued a $12.00 price target on shares of Amicus Therapeutics in a research report on Friday, June 30th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.25.

Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 16.24 on Thursday. The stock’s market cap is $2.67 billion. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $16.60. The stock’s 50 day moving average is $13.93 and its 200-day moving average is $10.49.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The business had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter last year, the business posted ($0.40) earnings per share. Equities analysts anticipate that Amicus Therapeutics will post ($1.31) EPS for the current fiscal year.

WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/amicus-therapeutics-inc-fold-given-buy-rating-at-chardan-capital.html.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Teacher Retirement System of Texas grew its holdings in Amicus Therapeutics by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares during the period. DORCHESTER WEALTH MANAGEMENT Co purchased a new stake in Amicus Therapeutics in the 2nd quarter valued at about $111,000. Tudor Investment Corp ET AL purchased a new stake in Amicus Therapeutics in the 2nd quarter valued at about $124,000. Aperio Group LLC grew its holdings in Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares during the period. Finally, Zacks Investment Management purchased a new stake in Amicus Therapeutics in the 2nd quarter valued at about $145,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.